- Home
- REG vs GMAB Comparison
REG vs GMAB Comparison
Compare REG & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REG
- GMAB
- Stock Information
- Founded
- REG 1963
- GMAB 1999
- Country
- REG United States
- GMAB Denmark
- Employees
- REG N/A
- GMAB N/A
- Industry
- REG Real Estate Investment Trusts
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- REG Real Estate
- GMAB Health Care
- Exchange
- REG Nasdaq
- GMAB Nasdaq
- Market Cap
- REG 12.5B
- GMAB 13.2B
- IPO Year
- REG 1993
- GMAB N/A
- Fundamental
- Price
- REG $71.02
- GMAB $23.31
- Analyst Decision
- REG Buy
- GMAB Buy
- Analyst Count
- REG 13
- GMAB 7
- Target Price
- REG $77.92
- GMAB $37.60
- AVG Volume (30 Days)
- REG 1.2M
- GMAB 1.2M
- Earning Date
- REG 07-29-2025
- GMAB 08-07-2025
- Dividend Yield
- REG 3.97%
- GMAB N/A
- EPS Growth
- REG 2.52
- GMAB 77.72
- EPS
- REG 2.14
- GMAB 21.62
- Revenue
- REG $1,547,928,000.00
- GMAB $3,646,881,232.00
- Revenue This Year
- REG $1.51
- GMAB $21.64
- Revenue Next Year
- REG $4.00
- GMAB $15.57
- P/E Ratio
- REG $33.20
- GMAB $1.08
- Revenue Growth
- REG 6.08
- GMAB 32.97
- 52 Week Low
- REG $63.44
- GMAB $17.24
- 52 Week High
- REG $78.18
- GMAB $27.94
- Technical
- Relative Strength Index (RSI)
- REG 47.72
- GMAB 59.73
- Support Level
- REG $70.66
- GMAB $21.00
- Resistance Level
- REG $72.21
- GMAB $22.90
- Average True Range (ATR)
- REG 1.41
- GMAB 0.46
- MACD
- REG -0.11
- GMAB 0.08
- Stochastic Oscillator
- REG 25.67
- GMAB 92.79
About REG Regency Centers Corporation
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 482 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.